Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice

Oncogene volume 25, pages 4483–4490 (2006)Cite this article

Abstract

The fundamental basis for immunotherapy of leukemia is that leukemic cells express specific antigens that are not expressed by normal hematopoietic cells. However, the host immune system appears to be tolerant to leukemia cells. To overcome this tolerance, we vaccinated immunocompetent mice with murine leukemia cells (WEHI-3B and BCR-ABL+ 32D cells) transduced with a specifically constructed transmembrane form of granulocyte–macrophage colony-stimulating factor (tmGM-CSF). The transduced cells expressed tmGM-CSF on the cell-surface. To determine whether tmGM-CSF-expressing WEHI-3B leukemia cells would prevent leukemia formation as a vaccine, immunocompetent mice (BALB/c and C3H/HEJ) were immunized with lethally irradiated murine leukemia cells expressing cell-surface tmGM-CSF before challenging mice with murine leukemia cells. Two immunocompetent mouse models were investigated, either WEHI-3B cells in BALB/c mice or BCR-ABL+ 32D cells in C3H/HEJ mouse. The results showed that 100% of WEHI-3B/tmGM-CSF-vaccinated BALB/c mice and about 65% of 32D+ BCR-ABL/tmGM-CSF-vaccinated C3H/HEJ mice were protected from leukemia after leukemia cell challenge, whereas all non-vaccinated mice succumbed to leukemia. Spleen and marrow cell suspensions from vaccinated mice challenged with WEHI-3B cells lacked detectable GFP+ WEHI-3B cells at 82 days post-challenge. A significant delay of death was observed in C3H/HEJ mice challenged with the very aggressive DA-1 cell line expressing BCR-ABL. Vaccination of mice with WEHI-3B/CD40L cells protected 80% of the mice from the WEHI-3B challenge. Notably, 60% of the WEHI-3B/BALB/c mice were also protected from leukemia when WEHI-3B/tmGM-CSF vaccination was carried out after the leukemia challenge. In order to determine whether cellular immunity is involved in this vaccine-mediated protection, either CD4+ or CD8+ T cells were depleted from mice after the WEHI-3B/tmGM-CSF vaccination. The results indicate that CD8+ T-cells mediated the protective immune response provided by the irradiated tmGM-CSF-expressing WEHI-3B cells. In addition, vaccination of nude mice did not provide protection from WEHI-3B leukemia induction. Importantly, 80% of non-vaccinated mice were also protected from a WEHI-3B cell challenge after receiving spleen cells from vaccinated mice 1 day before challenge with leukemia cells. These results indicate that overexpression of tmGM-CSF on the leukemia cell-surface can enhance the recognition of leukemic cells by CD8+ T cells, and can either prevent or significantly delay leukemia induction. These findings suggest that injection of irradiated leukemia cells expressing cell-surface-bound GM-CSF has the potential as an immunological approach to treat leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Acres B, Paul S, Haegel-Kronenberger H, Calmels B, Squiban P . (2004). Curr Opin Mol Ther 6: 40–47.

  • Bahnson AB, Dunigan JT, Baysal BE, Mohney T, Atchison RW, Nimgaonkar MT et al. (1995). J Virol Methods 54: 131–143.

  • Bitton RJ . (2004). Curr Opin Mol Ther 6: 17–26.

  • Bleier JI, Pillarisetty VG, Shah AB, DeMatteo RP . (2004). J Immunol 172: 7408–7416.

  • Butturini A, Gale RP . (1995). Cancer Treat Res 76: 299–314.

  • Daley GQ, Van Etten RA, Baltimore D . (1990). Science 16: 824–830.

  • de Vos S, Kohn DB, Cho SK, McBride WH, Said IW, Koeffler HP . (1998). Leukemia 12: 401–405.

  • Denaro M, Oldmixon B, Patience C, Andersson C, Down J . (2001). Gene Therapy 8: 1814–1815.

  • Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E et al. (2003). Blood 101: 3560–3567.

  • Fujimura T, Chamoto K, Tsuji T, Sato T, Yokouchi H, Aiba S et al. (2004). Immunol Lett 93: 17–25.

  • Galea-Lauri J . (2002). Immunology 107: 20–27.

  • Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, Tuting T et al. (2000). Gene Therapy 7: 2036–2040.

  • Greenberger JS, Sakakeeny MA, Humphries RK, Eaves CJ, Eckner RJ . (1983). Proc Natl Acad Sci USA 80: 2931–2935.

  • Larregina A, Morelli A, Kolkowski E, Fainboim L . (1996). Immunology 87: 317–325.

  • Ling X, Ma G, Sun T, Liu J, Arlinghaus RB . (2003). Cancer Res 63: 298–303.

  • Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM et al. (1995). Blood 85: 2507–2515.

  • Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C et al. (1998). Blood 92: 4778–4791.

  • Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM . (1998). J Virol 72: 8150–8157.

  • Naldini L, Blomer U, Glay P, Ory D, Mulligan R, Gage FH et al. (1996). Science 272: 263–267.

  • O'Keefe CL, Risitano AM, Maciejewski JP . (2004). Hematology 9: 189–198.

  • Platzbecker U, Ehninger G, Bornhauser M . (2004). Leuk Lymphoma 45: 447–453.

  • Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M . (2004). Eur J Immunol 34: 66–73.

  • Rojas R, Roman J, Herrera C, Alvarez MA, Ramirez R, Torres A . (2003). Leuk Res 27: 351–357.

  • Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D et al. (2002). Leukemia 16: 1637–1644.

  • Saudemont A, Jouy N, Hetuin D, Quesnel B . (2005). Blood 105: 2428–2435.

  • Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM et al. (1999). J Immunol 162: 7343–7349.

  • Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D . (2001). Gene Therapy 6: 1305–1312.

  • Vereecque R, Buffenoir G, Gonzalez R, Preudhomme C, Fenauz P, Quesnel B . (1999). Leuk Res 23: 413–416.

  • Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D et al. (2002). Gene Therapy 9: 1302–1311.

  • Zhao RC, McIvor RS, Griffin JD, Verfaillie CM . (1997). Blood 90: 4687–4698.

Download references

Acknowledgements

We thank Dr Inder Verma of the Salk Institute (San Diego, CA, USA) for providing the first-generation lentivirus plasmids, Dr Didier Trono of Geneva University (Geneva, Sweden) for providing pLOX plasmid, Dr Thomas Kipps from the University of California at San Diego for supplying the CD40L plasmid, Dr B Quesnel (Lille, France) for DA-1/DA1-3b cells and Ms Wendy Schober (Flow Cytometry and Image Analysis Core Facility, 5 P30 CA16672-29) for assistance in flow cytometry analysis. These studies were supported in part by funds from the Griffin Foundation and the Hendricks Foundation.

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    X Ling, M F Dietrich & M Andreeff

  2. Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Y Wang & R B Arlinghaus

Authors
  1. X Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M F Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Andreeff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R B Arlinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R B Arlinghaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ling, X., Wang, Y., Dietrich, M. et al. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 25, 4483–4490 (2006). https://doi.org/10.1038/sj.onc.1209477

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209477

Keywords

This article is cited by

Search

Advanced search

Quick links